Haleon PLC Sponsored ADR (DE:H6D)
NYSE:H6D
H6D Stock Chart & Stats
€7.80
€0.15(1.69%)
At close: 4:00 PM EST
€7.80
€0.15(1.69%)
Day’s Range― - ―
52-Week Range€7.35 - €9.65
Previous CloseN/A
Volume102.00
Average Volume (3M)0.00
Market Cap
€32.84B
Enterprise Value€37.08B
Total Cash (Recent Filing)€1.32B
Total Debt (Recent Filing)€8.59B
Price to Earnings (P/E)28.8
Beta0.29
Next Earnings
Jul 30, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding4,423,630,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.65
Price to Book (P/B)2.05
Price to Sales (P/S)3.12
P/FCF Ratio17.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.73Price Target Upside37.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.48
Revenue Forecast (FY)€13.24B
Bulls Say, Bears Say
Bulls Say
Strong, Diversified OTC Brand PortfolioLeading, diversified OTC brands (e.g., Sensodyne, Advil, Centrum) provide durable pricing power, shelf presence, and consumer loyalty across categories and geographies. This reduces single-category risk, supports repeat purchase economics and steadier cash flows versus niche players over time.
Improving Margins And Strong Cash ConversionGross and net margin expansion plus FCF near 86% of net income show structural cost and productivity gains. Durable margin improvement supports funding for A&P/R&D, deleveraging, and reorg savings, improving resilience to modest revenue slippage over the medium term.
E‑commerce And Channel Execution GainsStrong online share and rapid digital growth create a structural advantage as consumers shift channels. Higher digital share and improved media ROI enable more efficient customer acquisition, faster geographic expansion, and reduced dependence on single retail partners over the medium term.
Bears Say
Soft Top-line Growth And Low Volume TrendsPersistent low volume growth constrains sustainable revenue expansion and indicates reliance on pricing or mix to hit targets. If volumes remain below peer levels, the company may need ongoing elevated marketing spend or promotions to regain share, pressuring margins and medium‑term growth durability.
High Absolute Debt Stock Limits FlexibilityA sizable absolute debt balance (~$8.6B) reduces strategic flexibility despite improving ratios. High debt increases refinancing and interest exposure and can constrain investment cadence, share buybacks or agility during prolonged top-line weakness, making recovery pace more sensitive to cash generation.
Pharmacy Channel & Retailer Inventory UncertaintyStructural retailer destocking and potential ownership shifts threaten sell‑through and shelf placement, forcing incremental trade spend or promotional activity. Persistent channel disruption can reduce revenue visibility and necessitate margin‑dilutive tactics to defend placement and consumer awareness.
Haleon PLC Sponsored ADR News
H6D FAQ
What was Haleon PLC Sponsored ADR’s price range in the past 12 months?
Haleon PLC Sponsored ADR lowest stock price was €7.35 and its highest was €9.65 in the past 12 months.
What is Haleon PLC Sponsored ADR’s market cap?
Haleon PLC Sponsored ADR’s market cap is €32.84B.
When is Haleon PLC Sponsored ADR’s upcoming earnings report date?
Haleon PLC Sponsored ADR’s upcoming earnings report date is Jul 30, 2026 which is in 55 days.
How were Haleon PLC Sponsored ADR’s earnings last quarter?
Haleon PLC Sponsored ADR released its earnings results on Feb 25, 2026. The company reported €0.111 earnings per share for the quarter, beating the consensus estimate of €0.107 by €0.004.
Is Haleon PLC Sponsored ADR overvalued?
According to Wall Street analysts Haleon PLC Sponsored ADR’s price is currently Undervalued.
Does Haleon PLC Sponsored ADR pay dividends?
Haleon PLC Sponsored ADR does not currently pay dividends.
What is Haleon PLC Sponsored ADR’s EPS estimate?
Haleon PLC Sponsored ADR’s EPS estimate is 0.11.
How many shares outstanding does Haleon PLC Sponsored ADR have?
Haleon PLC Sponsored ADR has 4,423,630,400 shares outstanding.
What happened to Haleon PLC Sponsored ADR’s price movement after its last earnings report?
Haleon PLC Sponsored ADR reported an EPS of €0.111 in its last earnings report, beating expectations of €0.107. Following the earnings report the stock price went down -4.811%.
Which hedge fund is a major shareholder of Haleon PLC Sponsored ADR?
Currently, no hedge funds are holding shares in DE:H6D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.73 (37.60% Upside)
€10.73 (37.60% Upside)
Blogger Sentiment
Neutral
DE:H6D Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.62%
12-Months-Change
Fundamentals
Return on Equity
6.43%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
Haleon PLC Sponsored ADR
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
H6D Company Deck
H6D Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances clear operational and strategic progress (notably strong margin/cost improvements, Oral Health outperformance, emerging markets growth, increased A&P/R&D investment, and a planned $175–$200M cost saving reorganization) against meaningful top-line and volume challenges (soft U.S. market, cold & flu season weakness, category-specific headwinds, and regional retailer/inventory issues). Management presented realistic 2026 guidance (3%–5%) while reiterating confidence in returning to the 4%–6% medium-term ambition as U.S. performance, distribution gains, and productivity benefits materialize.View all DE:H6D earnings summariesH6D Stock 12 Month Forecast
Average Price Target
€10.73
▲(37.60% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Options Prices
Currently, No data available
---